Search results for " parkin"

showing 10 items of 122 documents

Ruolo degli estrogeni nella malattia di Parkinson

2007

Malattia di Parkinson estrogeniSettore MED/26 - Neurologia
researchProduct

Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort

2021

AbstractAim of the study was to evaluate possible associations between cognitive dysfunctions and development of Levodopa Induced Dyskinesia (LID). PD patients from the Parkinson’s disease Cognitive impairment Study cohort who underwent a baseline and follow-up neuropsychological evaluations were enrolled. Mild Cognitive Impairment (PD-MCI) was diagnosed according to MDS level II criteria. The following cognitive domains were evaluated: episodic memory, attention, executive function, visuo-spatial function and language. A domain was considered as impaired when the subject scored 2 standard deviation below normality cut-off values in at least one test for each domain. Levodopa equivalent dos…

Male0301 basic medicineDyskinesia Drug-InducedLevodopamedicine.medical_specialtyParkinson's diseaseScienceNeuropsychological TestsSeverity of Illness IndexArticleCohort StudiesLevodopaExecutive Function03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansAttentionCognitive DysfunctionLongitudinal StudiesAgedProportional Hazards ModelsLevodopa-induced dyskinesiaMultidisciplinarybusiness.industryQRNeuropsychologyParkinson DiseaseCognitionMiddle Agedmedicine.diseaseAged Attention Cognitive Dysfunction Cohort Studies Dyskinesia Drug-Induced Executive Function Female Humans Levodopa Longitudinal Studies Male Middle Aged Neuropsychological Tests Parkinson Disease Proportional Hazards Models Severity of Illness Index030104 developmental biologyNeurologyRisk factorsDyskinesiaCohortMedicineFemalemedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugCohort studyScientific Reports
researchProduct

Frequency and Correlates of Subjective Memory Complaints in Parkinson’s Disease with and without Mild Cognitive Impairment: Data from the Parkinson’s…

2018

Subjective memory complaints (SMC) may represent the preclinical phase of mild cognitive impairment (MCI) due to Alzheimer's disease. Dementia/MCI have been described with a high prevalence in Parkinson's disease (PD), but whether SMC may predict the development of cognitive impairment has been barely explored. To evaluate the frequency and clinical correlates of isolated SMC (PD-SMC) or within the construct of MCI in subjects with PD, 147 PD patients from the PArkinson's disease COgnitive impairment Study (PACOS) were consecutively recruited for the study. This is a multicenter study involving two Movement Disorder Centers in south Italy. All subjects underwent comprehensive neuropsycholog…

Male0301 basic medicineParkinson's diseaseParkinson's diseaseDiseaseNeuropsychological TestsAnxietyLogistic regressionExecutive Function0302 clinical medicineSurveys and QuestionnairesAttentionCognitive impairmentAged 80 and overGeneral NeuroscienceNeuropsychologyParkinson DiseaseGeneral MedicineMiddle Agedmusculoskeletal systemPsychiatry and Mental healthClinical PsychologyVisual Perceptioncardiovascular systemAnxietySettore MED/26 - NeurologiaFemaleAnxiety; cognitive impairment; disability; motor impairment; Parkinson's disease; subjective complaints; Neuroscience (all); Clinical Psychology; Geriatrics and Gerontology; Psychiatry and Mental Healthmedicine.symptommedicine.medical_specialtyStatistics Nonparametricmotor impairment03 medical and health sciencesInternal medicinemental disordersmedicineHumansDementiaAgedRetrospective Studiescognitive impairmentSubjective complaints Cognitive Impairment Parkinson’s Disease Disability Motor Impairment AnxietyMemory DisordersNeuroscience (all)subjective complaintsbusiness.industrymedicine.diseaseCross-Sectional Studies030104 developmental biologydisabilityEtiologyGeriatrics and GerontologyCognition Disordersbusiness030217 neurology & neurosurgeryJournal of Alzheimer's Disease
researchProduct

Mild cognitive impairment in Parkinson’s disease: the Parkinson’s disease cognitive study (PACOS)

2018

Approximately 30% of Parkinson's disease (PD) patients show impaired cognitive performance, which is suggestive of Mild Cognitive Impairment (MCI), representing a predictor of dementia, especially when present at diagnosis. The objective of the study was to evaluate the frequency and clinical predictors of MCI in a large hospital-based cohort of PD patients. We collected cross-sectional data from the Parkinson's disease cognitive impairment study (PACOS), a multicenter study involving two Movement Disorder centers, which are located in south Italy. The PD subjects were diagnosed according to the UK Brain Bank criteria and they underwent an extensive neuropsychological assessment. PD-MCI was…

Male0301 basic medicinemedicine.medical_specialtyNeurologyParkinson's diseaseEpidemiologyParkinson's diseaseNeuropsychological TestsLogistic regressionSeverity of Illness Index03 medical and health sciences0302 clinical medicineInternal medicinemental disordersEpidemiologyOdds RatioPrevalenceHumansMedicineDementiaCognitive DysfunctionParkinsonâ s diseaseEffects of sleep deprivation on cognitive performanceNeuropsychological assessmentAge of OnsetCognitive impairment; Epidemiology; Parkinson’s disease; Prevalence; Neurology; Neurology (clinical)AgedRetrospective Studiesmedicine.diagnostic_testbusiness.industryParkinson Diseasemedicine.diseasenervous system diseasesCross-Sectional StudiesCognitive impairment030104 developmental biologyNeurologyMultivariate AnalysisCohortEducational StatusSettore MED/26 - NeurologiaFemaleAmnesiaNeurology (clinical)businesshuman activities030217 neurology & neurosurgeryJournal of Neurology
researchProduct

Electrocortical networks in Parkinson's disease patients with Mild Cognitive Impairment. The PaCoS study

2019

Abstract Introduction Parkinson's Disease (PD) is frequently associated with cognitive dysfunction ranging from Mild Cognitive Impairment (PD-MCI) to dementia. Few electrophysiological studies are available evaluating potential pathogenetic mechanisms linked to cognitive impairment in PD since its initial phases. The objective of the study is to analyze electrocortical networks related with cognitive decline in PD-MCI for identifying possible early electrophysiological markers of cognitive impairment in PD. Methods From the PaCoS (Parkinson's disease Cognitive impairment Study) cohort, a sample of 102 subjects including 46 PD-MCI and 56 PD with normal cognition (PD-NC) was selected based on…

Male0301 basic medicinemedicine.medical_specialtyParkinson's diseaseQuantitative EEGElectroencephalographyAudiology03 medical and health sciences0302 clinical medicinemental disordersmedicineHumansDementiaCognitive DysfunctionNeuropsychological assessmentCognitive declineTomographyAgedElectrocortical networkElectrocortical networksmedicine.diagnostic_testbusiness.industryParietal lobeMild cognitive impairmentElectroencephalographyParkinson DiseaseCognitionMiddle Agedmedicine.disease030104 developmental biologyNeurologyFrontal lobeDisease ProgressionFemaleNeurology (clinical)Nerve NetElectrocortical networks; Mild cognitive impairment; Parkinson's disease; Quantitative EEG; Neurology; Geriatrics and Gerontology; Neurology (clinical)Geriatrics and GerontologyOccipital lobebusiness030217 neurology & neurosurgeryParkinsonism & Related Disorders
researchProduct

Cognitive and motor effects of Kinect‐based games training in people with and without Parkinson disease: A preliminary study

2019

Objective Purpose of this study is to evaluate the effects of training with six commercial Xbox KinectTM games on cognitive and motor aspects in Parkinson's disease (PD) patients and to compare the effects with a group of paired healthy subjects. Methods This study was a quasi-experimental, controlled trial. Eight individuals with PD (mean age 68.9 ± 7.9) and eight older adults without PD, matched by age (mean age 67.6 ± 7.3) were enrolled in the study. Ten sessions of six Xbox 360 KinectTM commercial games were performed for 5 weeks. Subjects were evaluated before and 7 and 30 days after intervention. They were assessed using Montreal Cognitive Assessment, Frontal Assessment Battery (FAB),…

Male030506 rehabilitationmedicine.medical_specialtymedicine.medical_treatmentcognition Parkinson's disease rehabilitation video gamesPhysical Therapy Sports Therapy and RehabilitationTimed Up and Go testlaw.invention03 medical and health sciencesCognition0302 clinical medicinePhysical medicine and rehabilitationRandomized controlled triallawRating scalemedicineHumansGaitPostural BalanceGait Disorders NeurologicAgedRehabilitationbusiness.industryMontreal Cognitive AssessmentParkinson DiseaseCognitionMiddle AgedExecutive functionsGaitVideo GamesTime and Motion StudiesFemale0305 other medical sciencebusiness030217 neurology & neurosurgeryPhysiotherapy Research International
researchProduct

Mutations in ATP13A2 (PARK9) are associated with an amyotrophic lateral sclerosis-like phenotype, implicating this locus in further phenotypic expans…

2019

Background Amyotrophic lateral sclerosis [1] is a genetically heterogeneous neurodegenerative disorder, characterized by late-onset degeneration of motor neurons leading to progressive limb and bulbar weakness, as well as of the respiratory muscles, which is the primary cause of disease fatality. To date, over 25 genes have been implicated as causative in ALS with C9orf72, SOD1, FUS, and TARDBP accounting for the majority of genetically positive cases. Results We identified two patients of Italian and French ancestry with a clinical diagnosis of juvenile-onset ALS who were mutation-negative in any of the known ALS causative genes. Starting with the index case, a consanguineous family of Ita…

MaleAmyotrophic lateral sclerosis ATP13A2 parkinsonismlcsh:Medicine0302 clinical medicineC9orf72Drug DiscoveryAmyotrophic lateral sclerosisIndex caseZebrafishExome sequencingMotor NeuronsGenetics0303 health sciencesDEMENTIA1184 Genetics developmental biology physiologyMiddle AgedPedigree3. Good healthProton-Translocating ATPasesPhenotypeMolecular MedicineFemaleSettore MED/26 - NeurologiaPrimary ResearchAdultlcsh:QH426-470SOD1BiologyTARDBP03 medical and health sciencesParkinsonian DisordersNeuronal Ceroid-LipofuscinosesExome SequencingGeneticsmedicineAnimalsHumansGenetic Predisposition to DiseaseMolecular Biology030304 developmental biologyGenetic heterogeneityAmyotrophic Lateral Sclerosislcsh:Rmedicine.diseaseDisease Models Animallcsh:GeneticsMutationNeuronal ceroid lipofuscinosis030217 neurology & neurosurgeryPARKINSONISM
researchProduct

Subthalamic deep brain stimulation improves time perception in Parkinson's disease.

2004

Alterations in temporal estimation have been observed in Parkinson's disease (PD) and have been associated with dopaminergic dysfunction. To investigate whether deep brain stimulation might reverse these abnormalities in PD, patients treated with electrode implantation for subthalamic deep brain stimulation were required to reproduce time intervals in different experimental conditions (off deep brain stimulation/off therapy, on deep brain stimulation/off therapy, on therapy/off deep brain stimulation). Patients treated with deep brain stimulation in off deep brain stimulation/off therapy displayed the anomalous pattern of responses typically observed in PD. When subthalamic deep brain stimu…

MaleDeep brain stimulationParkinson's diseaseDeep brain stimulation; Memory; Parkinsons disease; Time perception;Parkinson's diseasemedicine.medical_treatmentCentral nervous systemElectric Stimulation TherapyNOmemoryParkinsons diseaseBasal gangliamedicineHumansAnalysis of Variance; Parkinson Disease; Humans; Electric Stimulation Therapy; Time Perception; Aged; Middle Aged; Subthalamus; Male; FemaleDeep transcranial magnetic stimulationPrefrontal cortexAgedAnalysis of VarianceSettore M-PSI/02 - Psicobiologia E Psicologia Fisiologicabusiness.industryGeneral NeuroscienceDopaminergicParkinson DiseaseTime perceptionMiddle Agedmedicine.diseasedeep brain stimulationmedicine.anatomical_structureSubthalamusTime PerceptionSettore MED/26 - NeurologiaFemalebusinessNeuroscienceNeuroreport
researchProduct

rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease

2005

The neural mechanisms and circuitry involved in levodopa-induced dyskinesia are unclear. Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion. rTMS at 1 Hz was observed to markedly reduce drug-induced dyskinesias, whereas 5-Hz rTMS induced a slight but not significant increase.

MaleDyskinesia Drug-InducedApomorphinemedicine.medical_treatmentDopamineNeurological disorderNOCentral nervous system diseaseDegenerative diseasemental disordersNeural PathwaysmedicineHumansAgedSupplementary motor areaDyskinesiabusiness.industryDyskinesia Drug-Induced; Treatment Outcome; Male; Middle Aged; Female; Humans; Parkinson Disease; Motor Cortex; Recovery of Function; Apomorphine; Dopamine Agonists; Neural Pathways; Aged; Transcranial Magnetic Stimulation; DopamineMotor CortexParkinson DiseaseRecovery of FunctionMiddle Agedmedicine.diseaseSMA*Transcranial Magnetic Stimulationnervous system diseasesTranscranial magnetic stimulationApomorphinemedicine.anatomical_structureTreatment OutcomeDyskinesiaDrug-InducedDopamine AgonistsFemaleSettore MED/26 - NeurologiaNeurology (clinical)medicine.symptombusinessNeurosciencemedicine.drug
researchProduct

The "gender factor" in wearing-off among patients with parkinson's disease: A post hoc analysis of DEEP study

2014

Background. The early detection of wearing-off in Parkinson disease (DEEP) observational study demonstrated that women with Parkinson’s disease (PD) carry an increased risk (80.1%) for wearing-off (WO). This post hoc analysis of DEEP study evaluates gender differences on WO and associated phenomena.Methods. Patients on dopaminergic treatment for ≥1 year were included in this multicenter observational cross-sectional study. In a single visit, WO was diagnosed based on neurologist assessment as well as the use of the 19-item wearing-off questionnaire (WOQ-19); WO was defined for scores ≥2. Post hoc analyses were conducted to investigate gender difference for demographic and clinical features …

MaleGenetics and Molecular Biology (all)medicine.medical_specialtyLevodopaParkinson's diseaseArticle SubjectCross-sectional studylcsh:MedicineDiseaseAged; Akathisia Drug-Induced; Antiparkinson Agents; Cross-Sectional Studies; Female; Gait; Humans; Levodopa; Male; Parkinson Disease; Risk Factors; Severity of Illness Index; Sex Factors; Medicine (all); Biochemistry Genetics and Molecular Biology (all); 2300lcsh:TechnologySeverity of Illness IndexBiochemistryGeneral Biochemistry Genetics and Molecular BiologyAntiparkinson AgentsLevodopaSex FactorsRisk FactorsInternal medicinePost-hoc analysisSeverity of illnessBIO/14 FarmacologiamedicineHumansProspective cohort studylcsh:ScienceGaitGeneral Environmental ScienceAgedAged; Akathisia Drug-Induced; Antiparkinson Agents; Cross-Sectional Studies; Female; Gait; Humans; Levodopa; Male; Parkinson Disease; Risk Factors; Severity of Illness Index; Sex Factors; Biochemistry Genetics and Molecular Biology (all); 2300; Medicine (all)2300business.industrylcsh:TMedicine (all)lcsh:RParkinson DiseaseGeneral Medicinemedicine.diseaseAkathisiaCross-Sectional StudiesDrug-InducedPhysical therapyObservational studylcsh:QFemalebusinessAkathisia Drug-InducedResearch Articlemedicine.drug
researchProduct